|1.||Pustilnik, Leslie R: 1 article (08/2003)|
|2.||Iwata, Kenneth K: 1 article (08/2003)|
|3.||Boscoe, Brian P: 1 article (08/2003)|
|4.||Miller, Penny E: 1 article (08/2003)|
|5.||Jani, Jitesh P: 1 article (08/2003)|
|6.||Rossi, Ann Marie K: 1 article (08/2003)|
|7.||Liu, Zhengyu: 1 article (08/2003)|
|8.||Emerson, Erling: 1 article (08/2003)|
|9.||Provoncha, Kathleen: 1 article (08/2003)|
|10.||Cox, Eric D: 1 article (08/2003)|
08/01/2003 - "CP-654577 warrants further evaluation in tumors with high expression of p185(erbB2) and may differ from selective EGFr inhibitors or nonselective dual EGFr/erbB2 inhibitors in efficacy and therapeutic index."
08/01/2003 - "CP-654577 produced a dose-dependent reduction of p185(erbB2) autophosphorylation and inhibited the growth of these tumors. "
|2.||Breast Neoplasms (Breast Cancer)
08/01/2003 - "The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells."
08/01/2003 - "Treatment of SKBr3 human breast cancer cells with CP-654577 reduces the levels of the activated form of mitogen-activated protein kinase, increases the levels of cyclin-dependent kinase inhibitor p27(kip1) and reduces expression of cyclins D and E. "
|1.||Cyclin-Dependent Kinase Inhibitor p27
|3.||Protein Kinases (Protein Kinase)